Results of a survey on early prescribing patterns of emerging treatments for migraine prophylaxis indicate that clinicians anticipate decreased use of onabotulinumtoxinA and increased use of erenumab for episodic migraine treatment.
Researchers pooled data from 2 randomized, double-blind, placebo-controlled trials and found that noninvasive VNS is effective in aborting attacks in episodic cluster headache.
Researchers reviewed evidence relating to the benefits and harms of cranial electrical stimulation for adults with chronic painful conditions, depression, anxiety, and insomnia.
Treatment with lomerizine increases interictal regional cerebral blood flow and may reduce migraine in chronic migraineurs.
The Food and Drug Administration has accepted a Biologics License Application for the investigational migraine prevention treatment, galcanezumab.
A recently published article exposes a gaping hole in the access to an effective first-line therapy for a portion of patients with cluster headache in the United States.
There is a suggested link between migraine and the presence of patent foramen ovale, with the suggestion that PFO closure surgery might be a preventative measure against future migraine attacks, but what are the consequences?
A treatment of intravenous hydromorphone was found to provide less pain relief for acute migraine than IV prochlorperazine in patients admitted to the emergency department.
The stimulation of the transient receptor potential vanilloid 1 receptor may explain the benefits of capsaicin and hot water hydrotherapy in patients experiencing cannabinoid hyperemesis syndrome.
The FDA approved Duzallo, a fixed-dose tablet combining lesinurad and allopurinol, for the treatment of uncontrolled gout.
